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Complement-induced phospholipase A2 activation in experi- (PLA2) [1–3]. There are several isoforms of PLA2. “Se-
mental membranous nephropathy. cretory” forms (including groups IB, IIA and V sPLA2s)
Background. In the passive Heymann nephritis (PHN) appear to be active extracellularly at millimolar Ca21model of membranous nephropathy, C5b-9 induces glomerular
concentrations, do not show specificity for AA in theepithelial cell (GEC) injury and proteinuria, which is partially
sn-2 position of phospholipids, and may play a role inmediated by eicosanoids. By analogy, in cultured rat GEC,
sublytic C5b-9 injures plasma membranes and releases arachi- inflammation, or in the release of AA for metabolism to
donic acid (AA) and eicosanoids, due to activation of phospho- eicosanoids [4]. sPLA2s are generally localized in cellularlipase A2 (PLA2). This study addresses the mechanisms of PLA2 granules, are of low molecular mass (,15 kD), and areactivation.
found in a variety of organs, including kidney. The regu-Methods. PLA2 expression was assessed with the polymerase
lation of sPLA2 activity has not been elucidated defini-chain reaction or immunoblotting, and activity was determined
using an in vitro assay or by measurement of free AA. tively; however, activity may be regulated transcription-
Results. Under basal conditions, GEC in culture expressed ally, such as sPLA2 mRNA and protein may be induceda relatively low level of cytosolic PLA2 (cPLA2) protein, while by cytokines, or alternatively, by post-translationalmRNAs of groups IB, IIA and V secretory PLA2s (sPLA2)
mechanisms that remain to be characterized [4]. Cyto-were not detectable. Incubation of GEC with sublytic C5b-9
solic PLA2 (cPLA2 or group IV PLA2) is an ,85 kDinduced 1.5- to 2.0-fold increases in free [3H]AA at 40 minutes,
and three and 24 hours. C5b-9 did not increase cPLA2 protein, protein that is highly homologous in structure between
and did not induce group IB, IIA or V sPLA2 mRNAs. Stable species but is very distinct from the sPLA2s, and is pres-
overexpression of cPLA2 in GEC amplified the C5b-9-induced ent in the cytosol of a variety of cell types [5]. cPLA2 isincreases in free [3H]AA, while analogous overexpression of
activated by increases in cytosolic Ca21 concentrationgroup IIA sPLA2 had no effect. PLA2 activity was increased
([Ca21]i) in the micromolar range. Increased [Ca21]i mayin glomeruli of rats with PHN, and this enhanced activity was
characterized as cPLA2. There were no differences in cPLA2 lead to translocation of cPLA2 from the cytosol to an
protein expression between PHN and control glomeruli. intracellular membrane, where cPLA2 would bind via
Conclusions. Release of AA by C5b-9 in GEC in culture its N-terminal Ca21-dependent lipid binding domainand in vivo is mediated by cPLA2, and the mechanism is consis- [2, 3, 5]. Translocation would facilitate access of cPLA2tent with post-translational regulation of cPLA2 activity. C5b-9
to phospholipid substrate, and subsequently, access ofdoes not induce expression or stimulate activity of sPLA2 iso-
forms in GEC. free AA to metabolism by cyclooxygenase. The enzy-
matic activity of cPLA2 may be increased via phosphory-
lation [5]. Based on the relative specificity of cPLA2 for
Production of free arachidonic acid (AA) is the rate- AA in the sn-2 position, it has been proposed that the
limiting step in the synthesis of eicosanoids [1]. The ma- primary role of cPLA2 may be to release AA for synthesis
jor pathway for free AA production in most cells of eicosanoids; however, cPLA2 has also been shown to
is deacylation of phospholipids by phospholipase A2 play a role in cell injury [1, 5].
Insertion of the complement C5b-9 membrane attack
complex into plasma membranes of nucleated cells may
1 See Editorial by Shankland, p. 1204. lead to cell injury or lysis. Unlike erythrocytes, nucleated
cells require multiple C5b-9 lesions for lysis, and at lowerKey words: arachidonic acid, eicosanoids, glomerulonephritis, passive
Heyman nephritis, proteinuria, cell injury. doses, C5b-9 can induce sublytic injury, and several meta-
bolic effects [6, 7]. An example of this is the passiveReceived for publication July 13, 1999
Heymann nephritis (PHN) model of membranous ne-and in revised form October 7, 1999
Accepted for publication October 11, 1999 phropathy, where impairment of glomerular capillary
wall permselectivity (proteinuria) is mediated by anti-Ó 2000 by the International Society of Nephrology
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body and C5b-9 [8, 9]. The primary target of C5b-9 is the mmol), 1-palmitoyl-2-[arachidonoyl-14C]phosphatidylcho-
line (PC; 53 mCi/mmol), 1-palmitoyl-2-[arachidonoyl-visceral glomerular epithelial cell (GEC), which suffers
noncytolytic injury, appearing as effacement of foot pro- 14C]phosphatidylethanolamine (PE; 52 mCi/mmol), and
Na125I (2500 Ci/mmol) were purchased from New Eng-cesses, and villous transformation and vesiculation of the
plasma membranes [8, 9]. C5b-9 also stimulates produc- land Nuclear (Boston, MA, USA). Arachidonyl triflu-
oromethyl ketone (AACOCF3) was purchased from Bio-tion of glomerular eicosanoids [10–12], and thromboxane
(Tx) A2 may enhance proteinuria in certain models of mol Research Laboratories (Plymouth Meeting, PA,
USA). Thin layer chromatography plates (LK5DF) weremembranous nephropathy [11–14]. The effect of TxA2
may be through an increase in glomerular transcapillary obtained from Whatman (Clifton, NJ, USA). Lipids,
phorbol myristate acetate (PMA), lipopolysaccharidepressure, since this parameter is elevated in rat membra-
nous nephropathy, and appears to be responsible for a (LPS), and dithiothreitol (DTT) were purchased from
Sigma Chemical Co. (St. Louis, MO, USA). Electropho-portion of the enhanced urine protein excretion [15].
We have previously used well-differentiated rat GEC resis and immunoblotting reagents were from Biorad
Laboratories (Mississauga, Ontario, Canada). Plasmidsin culture to define biochemical pathways that are acti-
vated by sublytic C5b-9. By analogy to membranous pMT2-cPLA2 and pMT2-sPLA2 [20, 22] were kindly pro-
vided by Dr. J.D. Clark, Genetics Institute (Cambridge,nephropathy in vivo, sublytic C5b-9 injures plasma mem-
branes in cultured GEC [16]. In GEC, sublytic C5b-9 MA, USA).
acutely increases [Ca21]i, stimulates phospholipases C,
Cell culture and transfectionwhich leads to production of inositol phosphates and
diacylglycerol, and stimulates activities of protein kinase Rat GEC culture and characterization has been pub-
lished previously [16]. GEC were cultured in K1 mediumC (PKC) and extracellular signal-regulated kinase-2
(ERK2) [17–21]. In GEC extracts, sublytic C5b-9 in- on plastic substratum. GEC that stably overexpress
cPLA2 or group IIA sPLA2 were used in experimentscreased the activity of cPLA2 [22], and in GEC that stably
overexpress cPLA2 activity and protein (produced by where indicated, while neo GEC were used in the other
experiments. These clones of GEC were produced andtransfection of cPLA2 cDNA), acute incubation with
C5b-9 induced phosphorylation of cPLA2, and amplified characterized previously [20, 22]. Briefly, GEC were co-
transfected with the expression vector pMT2 (containingproduction of free AA and prostaglandin (PG) E2, as
compared with vector-transfected or parental GEC [22]. either cPLA2 cDNA or group IIA sPLA2 cDNA) and
pRc/RSV (molar ratio 12.5:1), using a CaPO4 transfec-Activation of cPLA2 also exacerbated complement-
induced GEC injury. In contrast, acute incubation of tion system. Colonies of GEC resistant to G418 were
isolated, and expanded. Transfectants were selected forGEC that overexpress group IIA sPLA2 with C5b-9 pro-
duced no significant amplication of AA release [20]. a high level of PLA2 protein expression (determined by
immunoblotting), and/or selection was carried out byThe present study further addresses the activation of
PLA2 isoforms by C5b-9 in GEC. We examined whether measuring PLA2 activity in cell fractions, using exoge-
nous 2-[arachidonoyl-14C]PE vesicles as substrate (seechronic exposure of GEC to sublytic C5b-9 affected in-
duction of PLA2 mRNA, protein, or activity. Our results below). A clone of GEC containing only the neomycin-
resistance gene was used as a control (clone neo). Com-indicate that C5b-9 does not induce transcription or
translation of sPLA2 or cPLA2 isoforms, and that the pared with parental or neo GEC, PLA2 activity was in-
creased ,fivefold in GEC that overexpress cPLA2, andC5b-9-mediated increase in PLA2 activity is due to post-
translational regulation of cPLA2. These findings were ,13-fold in GEC that overexpress sPLA2 [20, 22].
COS-1 cells were cultured in DMEM-10% fetal calfextended to C5b-9-induced GEC injury in vivo, by show-
ing that PLA2 activity is enhanced in glomeruli of rats serum (FCS). Transient transfection was carried out by
adding 6 mg of plasmid DNA in 50 mmol/L Tris buffer,with PHN, and that the enhanced PLA2 activity is charac-
teristic of cPLA2. pH 7.3, containing DEAE-dextran (0.2 mg/mL) to 1 3
106 cells for 18 hours. Cells were then incubated with
chloroquine (0.05 mg/mL) for five hours, and were har-
METHODS
vested after 48 hours [20].
Materials
Incubation of glomerular epithelial cellsTissue culture media, Trizol reagent, SuperScript one-
with complementstep reverse transcriptase polymerase chain reaction
(RT-PCR) system, Transfinity CaPO4 transfection sys- The standard protocol involved incubation of GEC in
monolayer culture (35 mm plates) with rabbit anti-GECtem, and G418 (geneticin) were obtained from Life Tech-
nologies (Burlington, Ontario, Canada). Complement- antiserum (5 to 10% vol/vol) in modified Krebs-Hensel-
eit buffer containing 145 mmol/L NaCl, 5 mmol/L KCl,deficient sera and purified C8 and C9 were purchased
from Quidel (San Diego, CA, USA). [3H]AA (100 Ci/ 0.5 mmol/L MgSO4, 1 mmol/L Na2HPO4, 0.5 mmol/L
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CaCl2, 5 mmol/L glucose, and 20 mmol/L Hepes, pH 7.4, centrifugation, the supernatant of the second homogeni-
for 40 minutes at 228C [17–22]. GEC were then incubated zation was combined with that of the first, and was centri-
with normal human serum (NS; 2.5% vol/vol in Krebs- fuged for one hour at 100,000 3 g to obtain the postnu-
Henseleit buffer), or with heat-inactivated (decomple- clear membrane pellet. The 100,000 3 g supernatant was
mented) human serum (HIS; 568C) in controls, at 378C. the cytosolic fraction [20].
In some experiments, antibody-sensitized GEC were in- Whole cell lysates were prepared by the addition of
cubated with 2.5% C8-deficient human serum (C8DS) lysis buffer to cells (1% Triton X-100, 125 mmol/L NaCl,
supplemented with purified C8 (80 mg/mL undiluted se- 10 mmol/L Tris, 1 mmol/L EDTA, 1 mmol/L EGTA, 20
rum), or with C8DS alone in controls. We have generally mmol/L leupeptin, 20 mmol/L pepstatin, and 0.1 mmol/L
used heterologous complement in order to facilitate stud- phenylmethylsulfonylfluoride, pH 7.4. Detergent-insol-
ies with complement-deficient sera, and to minimize pos- uble material was pelleted by centrifugation for three
sible signaling via complement-regulatory proteins; how- minutes at 15,000 3 g, and supernatants were then used
ever, in earlier studies, results of several experiments for immunoblotting.
were confirmed with homologous (rat) complement.
Sublytic concentrations of complement (#5% NS) were Expression of PLA2 isoforms
established previously [22]. In GEC, complement is not Secretory PLA2 mRNA was measured using RT-PCR.
activated in the absence of antibody, and antibody does Total RNA was isolated from GEC, using Trizol reagent,
not independently affect free [3H]AA [17–22]. according to the manufacturer’s instructions. cDNA syn-
To quantitate C9 binding, purified human C9 was io- thesis and PCR were performed in a single tube, using
dinated to a specific activity of 1 3 106 cpm/mg, using the SuperScript one-step RT-PCR System. The reaction
immobilized chloramine T [18]. GEC in monolayer cul- mixture included 1 mg RNA, 200 nmol/L sense and anti-
ture were incubated (as above) with antibody, followed sense primers, 1.2 mmol/L Mg21, 200 mmol/L deoxy-
by 2.0% C9-deficient human serum supplemented with nucleotide triphosphate, and Superscript/Taq polymer-
125I-C9 (0.075 mg/mL; 8 3 105 cpm/mL) and “cold” C9 ase. cDNA synthesis was carried out for 30 minutes at
(1.075 mg/mL). HIS containing 125I-C9 was used in con- 558C, followed by denaturation at 948C for two minutes.
trols (nonspecific binding). At the end of incubations, The PCR cycle was 15 seconds at 948C (denaturation),
cells were washed, and were then lyzed with 0.25 N 30 seconds at 608C (annealing), and one minute at 728C
NaOH. The radioactivity was measured in a g-counter. (extension). PCR products were visualized on 2% aga-
Specific binding of C9 was determined by subtracting rose gels, after staining with ethidium bromide. Group
cell-bound radioactivity of incubations with HIS con-
IB sPLA2 primers were CCTCGCCAAGATGAAAtaining 125I-C9 from incubations with C9-deficient serum
CTCC and CGGTGCAGAAATAAGACAGC (ex-containing 125I-C9 [18]. Nonspecific binding constituted
pected product 513 bp), as described previously [24].13 6 1% of total.
Group IIA sPLA2 primers were GAGTTTGGGCA
AATGATTCTGT and AAACATTCAGCGGCAGCInduction of passive Heymann nephritis
TTTA (expected product 287 bp). Group V sPLA2 pri-Passive Heymann nephritis was induced by a single
mers were CAGGGGGCTTGCTAGAACTGAA andintravenous injection of 0.4 mL of sheep anti-rat Fx1A
AAGACGGTTGTAACTCCAGAGG (expected prod-antiserum [23]. Urine was collected overnight, at day
uct 339 bp). The group IIA and V primers were based13–14 postinjection. Glomeruli were isolated by differen-
on analogous mouse sPLA2 primers described previouslytial sieving on day 14 [23], and were suspended in buffer
[25]. Since the specificities of the primer pairs have beenfor preparation of cell fractions (discussed later in this
established previously by use of Southern blotting [25],article).
we did not confirm these in the present study. Results
presented are representative of two to four experiments.Preparation of cell fractions or lysates
Expression of cPLA2 protein was determined by im-Cells or isolated glomeruli were centrifuged and resus-
munoblotting [22], using rabbit anti-cPLA2 antiserumpended in homogenization buffer, containing 50 mmol/
[22].L Hepes, 0.25 mol/L sucrose, 1 mmol/L ethylenedia-
minetetraacetic acid (EDTA), 1 mmol/L ethylenebis(ox-
Measurement of free [3H]AAyethylene-nitrilo)tetra-acetic acid (EGTA), 20 mmol/L
Glomerular epithelial cell phospholipids were labelledleupeptin, 20 mmol/L pepstatin, and 0.1 mmol/L phenyl-
to isotopic equilibrium with [3H]AA for 48 to 72 hours,methylsulfonylfluoride, pH 7.4 [20]. Cells were homoge-
as detailed previously [17–22]. Lipids were extractednized with 25 strokes in a homogenizer. The homogenate
from ,1 3 106 cells and cell supernatants. Methods forwas centrifuged at 1300 3 g for five minutes to sediment
extraction and separation of radiolabeled lipids by thinnuclei. The supernatant was removed, and the pellet
was homogenized for a second time, as above. After layer chromatography are published [17–22].
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Fig. 1. Assembly of sublytic C5b-9 complexes in glomerular epithelial
cells (GEC). Assembly of C5b-9 was monitored by quantitating specific
binding of 125I-C9. GEC were incubated with antibody, followed by
2.0% C9-deficient human serum supplemented with 125I-C9. HIS con-
taining 125I-C9 was used in controls (nonspecific binding). Values repre-
sent 3–6 experiments.
In vitro assay for PLA2 activity in intact GEC
1-Palmitoyl-2-[arachidonoyl-14C]PE or PC was sus-
Fig. 2. Effect of complement on sPLA2 mRNAs. GEC were untreatedpended in 2 mL of dimethylsulfoxide, and pipetted into (U), or were incubated with antibody and then with 2.5% NS (to form
microcentrifuge tubes (final assay concentration 3.5 sublytic C5b-9), or with HIS in controls, for 24 hours at 378C. Total
RNA was isolated and presence of sPLA2 mRNAs (groups IB, IIA andmmol/L; 50 mL volume) [20, 22]. Reactions were initiated
V) was assessed by RT-PCR. Positive control reactions (1) includedby adding cytosolic fraction (10 mg of glomerular protein total RNA from spleen (group IB) or intestine (groups IIA and V).
or 1 mg of COS cell protein per assay) and generally 4
mmol/L Ca21 (2 mmol/L in excess of EDTA and EGTA
concentrations in homogenization buffer). The mixture
was incubated for 30 minutes at 378C, and free [14C]AA C5b-9 complexes remained assembled in cell membranes
was separated by thin layer chromatography [20, 22]. until at least 24 hours. Based on these results, it was
reasonable to propose that the assembled C5b-9 com-
Statistics plexes can potentially induce chronic effects in GEC, in
Data are presented as mean 6 SEM. The t statistic addition to the acute effects reported previously [17–22].
was used to determine significant differences between
Complement does not affect PLA2 expressiontwo groups. Analysis of variance (ANOVA) was used to
determine significant differences among groups. Where In earlier studies, we used an in vitro PLA2 assay to
significant differences were found, individual compari- demonstrate that acute incubation of GEC with sublytic
C5b-9 (40 min) increased cPLA2 activity, but had nosons were made between groups using the t statistic, and
significant effect on the activity of a PLA2 of ,15 kDadjusting the critical value according to the Bonferroni
[20]. Furthermore, overexpression of cPLA2, but notmethod.
group IIA sPLA2, in GEC amplified release of [3H]AA
during acute incubation with C5b-9 (30 to 60 min), in
RESULTS
keeping with the increase in cPLA2 activity [20, 22]. In
Formation of C5b-9 the present study, we assessed if chronic incubation of
GEC with a sublytic concentration of complement af-Assembly of sublytic C5b-9 complexes in GEC was
monitored by quantitating binding of 125I-C9. Incubation fected expression or activity of PLA2 isoforms. First, we
assessed mRNA expression of three sPLA2 isoforms,of antibody-sensitized GEC with C9-deficient serum sup-
plemented with 125I-C9 demonstrated specific C9 binding groups IB, IIA and V, using RT-PCR. Under basal condi-
tions, that is, in unstimulated GEC, or in GEC incubatedat 30 minutes (Fig. 1). Binding of C9 increased steadily
up to two hours, and then more slowly until six hours. with antibody and HIS (Fig. 2), there was either no
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Fig. 4. Expression of cPLA2 protein. (A) Neo GEC were incubated
with antibody and 2.5% NS (to form C5b-9), antibody and 2.5% HIS,
and PMA (250 ng/mL), EGF (100 ng/mL) or LPS (10 mg/mL) in the
presence of serum for 24 hours at 378C. Lysates were immunoblotted
with anti-cPLA2 antibody. A faint band is present in all incubations.
On this blot, incubation with LPS resulted in a slight increase in the
intensity of the cPLA2 band, however, this finding was not consistent
between experiments. (B) Antibody-sensitized GEC that overexpress
cPLA2 were incubated with NS or HIS for 3 or 24 hours. Lysates were
immunoblotted with anti-cPLA2 antibody.
Fig. 3. Effect of LPS or PMA on sPLA2 mRNA. GEC were incubated
with LPS (10 mg/mL) or PMA (250 ng/mL) in the presence of 10%
FCS, or with 10% FCS alone for 24 hours at 378C. To assess for superin-
duction of mRNA, GEC were incubated with PMA 1 cycloheximide PMA 1 cycloheximide (superinduction of mRNA). In(CHX; 10 mg/mL). Total RNA was isolated and sPLA2 mRNAs (groups
some experiments, PMA increased group IIA and VIB, IIA and V) were assessed by RT-PCR. Positive control reactions
(1) included total RNA from spleen (group IB) or intestine (groups sPLA2 mRNAs modestly, but the effects of PMA were
IIA and V). not consistent between experiments. There was no obvi-
ous induction of group IB sPLA2 mRNA.
Changes in cPLA2 protein expression were studied by
immunoblotting. In keeping with prior results [20, 22],detectable mRNA or very faint PCR products for the
there is low basal expression of cPLA2 in GEC incubatedthree sPLA2 isoforms. In contrast, by RT-PCR, group
with HIS, as reflected by a faint band on immunoblotsIB sPLA2 was readily detected in spleen, while groups
(Fig. 4A). Incubation of GEC with complement (NS),IIA and V were present in intestine (Fig. 2). Incubation
PMA, epidermal growth factor (EGF), or LPS for 24of GEC with antibody and complement (NS) for 24 hours
hours did not enhance cPLA2 protein expression signifi-did not produce any significant increases in the mRNA
cantly.levels of the three sPLA2 isoforms (Fig. 2). Similar results
were evident after three and six hours of complement
Complement stimulates [3H]AA releaseincubation (data not shown).
In these experiments, we examined the effects of com-To determine if any of these sPLA2 mRNAs could be
plement on [3H]AA release in GEC that were trans-induced in GEC by other agonists, cells were incubated
fected to stably overexpress cPLA2 or group IIA sPLA2,for 24 hours with 10% FCS, PMA 1 FCS, or LPS 1 FCS.
and in vector-transfected (neo) GEC (Methods section).FCS alone had no significant effect on sPLA2 expression
First, antibody-sensitized neo GEC were incubated with(Fig. 3). LPS produced modest increases in mRNA for
complement (NS), or HIS (control incubations) for upgroups IIA and V sPLA2, but no change in group IB
to 24 hours. NS produced a significant increase in freesPLA2. The increases in group IIA and V sPLA2 mRNAs
were smaller than those observed in GEC treated with [3H]AA ranging from ,150 to 200% of control levels at
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Table 1. Effect of C5b-9 on free [3H] arachidonic acid ([3H]AA)
Free [3H]AA % total radioactivity
40 min 3 hours
C8DS 1 C8 1.9860.51a 5.4760.47b
C8DS 0.6060.08 1.5760.42
HIS 0.5760.03 1.2560.20
[3H]AA-labelled glomerular epithelial cells (GEC) that overexpress cytosolic
phospholipase A2 (cPLA2) were incubated with antibody and 2.5% C8 deficient
human serum (C8DS) reconstituted with purified C8 (C8DS 1 C8), C8DS alone,
or heat-inactivated (decomplemented) human serum (HIS). Significant differ-
ences were present among groups (40 min, ANOVA P , 0.03, aP , 0.02 C8DS 1
C8 vs. C8DS, 3 experiments; 3 hours, ANOVA P , 0.0005, bP , 0.0002 C8DS 1
C8 vs. C8DS, 3 experiments).
(Table 1). By analogy to Figure 5, C8DS 1 C8 stimulated
Fig. 5. Effect of complement on free [3H]AA. Neo GEC (r), GEC significant increases in free [3H]AA, as compared with
that overexpress cPLA2 (s), and GEC that overexpress group IIA C8DS. Moreover, the level of free [3H]AA in C8DSsPLA2 (d) were labelled with [3H]AA, and were incubated with anti-
body and 2.5% NS (to form C5b-9), or HIS in controls. Significant incubations was comparable to incubations with HIS,
complement-induced increases in free [3H]AA acid were present in all indicating that the C5b-7 complex was inactive.
groups (neo, ANOVA P , 0.03, P , 0.025 vs. control at 40 min, 3 h
Since LPS produced small increases in group IIA andand 24 h, respectively; cPLA2 overexpression, ANOVA P , 0.001,
P , 0.002 vs. control at 40 min, 3 h and 24 h, respectively; sPLA2 V sPLA2 mRNAs (Fig. 3), we assessed whether incuba-
overexpression, ANOVA P , 0.02, P , 0.01 vs. control at 24 h). Values tion of neo GEC with LPS would also lead to changes
represent 4 to 6 experiments for neo and cPLA2 overexpression, and in free [3H]AA. Neo GEC were incubated with 10%3 to 4 experiments for sPLA2 overexpression. In control incubations,
the ranges in the levels of free [3H]AA (% of total radioactivity) were FCS in medium with or without LPS, 10 mg/mL, for 24
0.55 to 1.42 in neo GEC, 0.94 to 1.83 in GEC that overexpress cPLA2, hours. Free [3H]AA levels were not significantly different
and 0.93 to 1.19 in GEC that overexpress sPLA2. between groups: FCS, 1.38 6 0.41% of total radioactivity,
and LPS 1 FCS 1.31 6 0.96% (4 experiments performed
in duplicate). Thus, the apparent increases in sPLA2
mRNAs were either not translated into increases in40 minutes, three hours and 24 hours (Fig. 5). Since the
sPLA2 proteins, or the amounts of sPLA2 proteins pro-studies on PLA2 expression had not demonstrated any
duced were trivial and insufficient to affect levels of freesignificant effect of complement on sPLA2 mRNA or
[3H]AA.cPLA2 protein induction, the changes in [3H]AA release
were most likely mediated through post-translational
PLA2 activity is enhanced in PHNmechanisms. To address this possibility, we then assessed
[3H]AA release in clones of GEC that overexpress In the above studies, we employed GEC in culture to
characterize PLA2 activation by C5b-9. It is important,cPLA2 or group IIA sPLA2. Complement-induced re-
lease of [3H]AA was markedly amplified in GEC that however, to demonstrate that analogous pathways are
activated in vivo, specifically, in the PHN model of mem-overexpress cPLA2 (Fig. 5). The effect was evident after
40 minutes of incubation and persisted at 3 and 24 hours. branous nephropathy, where C5b-9 assembles in GEC
plasma membranes and induces sublytic injury. StudiesIn contrast, there was no significant amplication of
[3H]AA release in GEC that overexpress sPLA2 (Fig. were carried out in rats during the autologous phase
of PHN (day 14), which is known to be complement-5). We also verified that incubation of cPLA2-transfected
GEC with complement did not produce a detectable mediated [8, 26], and at which time rats demonstrated
severe proteinuria (.180 mg/24 h; normal ,25 mg/24 h).change in the level of cPLA2 protein expression (Fig.
4B), indicating that activation of cPLA2 by complement Measurements of AA release, as performed in cul-
tured GEC, are not practical for assessment of PLA2was most likely post-translational. It should be noted
that the amount of cPLA2 activity/protein in the GEC activity in vivo. Therefore, cytosolic fractions were pre-
pared from glomeruli isolated from rats with PHN andthat overexpress cPLA2 is within a physiological range
[22], strongly suggesting that the results in these cells from control rats, and were assayed directly for PLA2
activity using [14C]PE or [14C]PC as substrate. PLA2 activ-are biologically relevant.
To verify that the effect of complement on [3H]AA ity was increased ,1.5-fold in glomeruli of rats with PHN
(Fig. 6A). In preliminary studies, where the subcellularrelease was actually due to assembly of C5b-9, antibody-
sensitized GEC that overexpress cPLA2 were incubated distribution of PLA2 activity was examined in fractions
of COS-1 cells that had been transiently transfected withwith C8DS reconstituted with purified C8 (to form
C5b-9), with C8DS alone (to form C5b-7), or with HIS cPLA2 or group IIA sPLA2, we demonstrated that cPLA2
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Fig. 6. PLA2 activity in PHN. (A) Cytosolic
fractions were prepared from glomeruli, iso-
lated from rats with PHN (day 14) and from
control rats, and were assayed for PLA2 activity
using [14C]PE or [14C]PC at 2 mmol/L free Ca21.
Significant differences were present between
PHN and control (*P 5 0.04; PE, 7 rats per PC,
4 rats per group). (B) PLA2 activity in cytosolic
fractions of glomeruli isolated from rats with
PHN, or control rats, and COS-1 cells trans-
fected with either cPLA2 or group IIA sPLA2
was assayed using [14C]PE or [14C]PC at 2
mmol/L free Ca21. Results are presented as
the ratio of PC to PE (%). sPLA2 activity
demonstrated significantly lower PC/PE ratio,
as compared with the other groups (ANOVA
P , 0.035, **P , 0.05, 3–12 experiments). (C)
Inhibition of PLA2 activity with AACOCF3
(10 mmol/L) or DTT (3 mmol/L, 30 min prein-
cubation) in cytosolic fractions of glomeruli
from rats with PHN, control rats, and COS-1
cells transfected with either cPLA2 or group
IIA sPLA2, assayed using [14C]PE at 2 mmol/L
free Ca21. Results are presented as percentage
of untreated (1P , 0.0001, 11P , 0.01 vs.
untreated, 3 to 5 experiments). (D) Ca21-de-
pendence of PLA2 activity in cytosolic frac-
tions of glomeruli isolated from normal rats,
assayed using [14C]PE (3 experiments). Free
Ca21 concentrations were produced using var-
ious combinations of CaCl2 and EGTA.
is found mainly in the cytosolic fraction, while sPLA2 is activities with PE versus PC demonstrated that sPLA2
was active in the presence of PE, but there was onlyboth membrane-associated and in the cytosol (data not
shown). Accordingly, glomerular cytosolic PLA2 activity minimal activity with PC, that is, the ratio of PC/PE
was ,10% (Fig. 6B). In contrast, cPLA2 demonstratedmay have included both cPLA2 and sPLA2 isoforms.
Moreover, it should be noted that preparation of glomer- substantial activity with both PE and PC (PC/PE ,60%),
while the PLA2 in PHN and control glomeruli was alsoular and COS-1 cell cytosol was carried out in Ca21-free
homogenization buffer. Consequently, it was expected active with both PE and PC substrates (Fig. 6B). Second,
the cPLA2-selective inhibitor, AACOCF3 (10 mmol/L)that if some of the cPLA2 was membrane-associated in
vivo, in the absence of Ca21, the cPLA2 would be released [27], blocked cPLA2 activity in COS-1 cytosol, but had
no significant effect on sPLA2 activity, while 30 minutefrom membranes. The in vitro PLA2 assay was, however,
carried out at a saturating concentration of free Ca21 (2 preincubation of COS-1 cytosolic fractions with 3
mmol/L DTT (to disrupt disulfide linkages in sPLA2 [4])mmol/L), implying that enhanced PLA2 activity in PHN
reflected a stable modification of a PLA2 isoform, or an inhibited sPLA2 activity, but had no significant effect on
cPLA2 (Fig. 6C). The pattern of PLA2 inhibition in PHNincrease in total amount of enzyme.
Several additional studies were carried out to charac- glomeruli closely resembled that of cPLA2, although the
inhibitory effect of AACOCF3 was not as complete (Fig.terize glomerular cytosolic PLA2 activity in PHN. In
these experiments, glomerular PLA2 activity was com- 6C). In control glomeruli (which have a lower level of
total PLA2 activity, as compared with PHN), AACOCF3pared with the activities of cPLA2 or group IIA sPLA2
expressed in COS-1 cells by transient transfection. inhibited PLA2 activity significantly, although less than
in PHN glomeruli, while DTT did not show a significant(There is only trivial PLA2 activity in untransfected
COS-1 cells; data not shown). First, it has been reported inhibitory effect. Together, the results indicate that con-
trol glomeruli contain substantial cPLA2 activity, butthat cPLA2 can hydrolyze both PE and PC substrates,
while sPLA2 is relatively inactive against PC [2]. Thus, there is most likely some sPLA2 or other uncharacterized
PLA2 activity as well. In PHN glomeruli, which containPLA2 activity in cytosolic fractions of glomeruli from
rats with PHN, or control rats, as well as COS-1 cells more total PLA2 activity than control, the characteristics
of the PLA2 activity are most consistent with cPLA2.transfected with either cPLA2 or sPLA2, was assayed
using [14C]PE or [14C]PC substrates. Comparison of PLA2 Finally, glomerular PLA2 was active at micromolar Ca21
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perfused kidney provide evidence that assembled C5b-9
also persists in GEC in vivo [29]. Chronic exposure of
GEC to C5b-9 resulted in a sustained increase in free
AA (Fig. 5). Overexpression of cPLA2 greatly amplified
C5b-9-mediated AA release, indicating that C5b-9 cou-
ples to cPLA2 (Fig. 5). The increase in AA was not,Fig. 7. Expression of cPLA2 in glomeruli of rats with PHN and normal
(control) rats. Representative immunoblot of two rats per group shows however, associated with changes in cPLA2 protein ex-
that there are no significant differences in expression of cPLA2 protein. pression (Fig. 4), suggesting that cPLA2 activity was regu-
lated post-translationally. In contrast, chronic exposure
to complement did not affect mRNA expression of sev-
eral sPLA2 isoforms (Fig. 2), and stable overexpression
of group IIA sPLA2 did not affect AA release (Fig.concentrations (Fig. 6D), in keeping with cPLA2 [1, 5].
5). Thus, the pattern of PLA2 activation during chronicIt should also be noted that glomeruli have no significant
exposure to C5b-9 resembled changes observed afterCa21-independent PLA2 activity (Fig. 6D). Thus, even
acute stimulation, and it appears that chronic stimulationthough AACOCF3 was reported to cross-inhibit Ca21-
with C5b-9 leads to a sustained increase in free AA.independent PLA2 [28], it is very unlikely that this could
Previously, we demonstrated that C5b-9 regulateshave occurred in PHN glomeruli.
cPLA2 activity in GEC via both an increase in [Ca21]iImmunoblot analysis of glomerular cytosolic fractions
and phosphorylation [20–22]. Reduction in extracellulardemonstrated similar amounts of cPLA2 protein in PHN
Ca21 concentration decreased the C5b-9-induced rise inand control rats (Fig. 7), suggesting that the increased
AA, while mutagenesis studies showed that deletion ofcPLA2 activity in PHN was due to post-translational reg-
the Ca21-dependent lipid binding domain of cPLA2 abol-ulation. Group IB, IIA, and V sPLA2 mRNAs were
ished AA release in the presence of Ca21. Moreover,detected by RT-PCR in glomeruli isolated from rats with
expression of a mutant form of cPLA2 that is membrane-PHN and controls, but there were no significant differ-
associated enabled complement-dependent AA releaseences between the two groups (data not shown). These
in a Ca21-independent manner [20]. Thus, the C5b-9-results are in keeping with measurements of PLA2 activ-
induced increase in [Ca21]i facilitates membrane-associa-ity (Fig. 6), which do not support a role for increased
tion of cPLA2 and phospholipid hydrolysis. Release ofsPLA2 activity in PHN.
AA by C5b-9 in GEC also involves phosphorylation of
cPLA2 via PKC or a kinase downstream of PKC, al-DISCUSSION though phosphorylation occurs independently of the
To our knowledge, this is the first study that directly ERK pathway [20, 21]. For example, pharmacological
addresses PLA2 activation in immune glomerular injury. inhibition or down-regulation of PKC blocks C5b-9-
The present study, together with those performed pre- induced activation of cPLA2 and AA release [20–22]. On
viously, defines the regulation of PLA2 activity by C5b-9 the other hand, inhibition of the complement-dependent
in GEC in culture and in experimental membranous increase in ERK activity had no effect on complement-
nephropathy. In an earlier study, we used an in vitro induced AA release, and complement was able to acti-
assay of PLA2 activity to demonstrate that acute incuba- vate a mutant form of cPLA2, which was lacking the
tion of cultured GEC with sublytic C5b-9 increased ERK phosphorylation site (serine505) [21]. Thus, while
cPLA2 activity, but had no effect on sPLA2 activity [22]. cPLA2 activation in GEC involves phosphorylation, the
Furthermore, stable overexpression of cPLA2, but not kinase(s) differs from the model originally proposed by
group IIA sPLA2 in GEC amplified the acute C5b-9- Lin et al [30], who concluded that serine505 phosphoryla-
induced release of [3H]AA that occurs in parental GEC, tion by ERK is solely responsible for cPLA2 activation.
in keeping with the ability of C5b-9 to increase cPLA2 Transcriptional/translational regulation of cPLA2 has
activity [20]. The present study addressed changes in been reported [31], but this mechanism appeared not to
PLA2 activity that occur during chronic exposure of GEC be involved in GEC.
to C5b-9. Assembly of C5b-9 in GEC membranes was In contrast to cPLA2, activation of sPLA2 did not ap-
evident within 30 minutes of incubation with comple- pear to play a role in complement-induced AA release
ment. The number of C5b-9 complexes increased during in GEC. The understanding of sPLA2 regulation is in-
the first six hours of incubation, and the assembled com- complete; however, it appears that certain sPLA2 activi-
plexes persisted for at least 24 hours (Fig. 1). The persis- ties may be regulated via transcription or by post-transla-
tence of assembled C5b-9 in GEC membranes differs tional mechanisms [4, 32, 33]. Furthermore, it has been
from findings in other cells, such as neutrophils, where proposed that activation of cPLA2 may be a prerequisite
C5b-9 is eliminated within several minutes [6]. However, for induction of sPLA2 [32, 33]. Previously, we demon-
strated that resting GEC contain a small amount of anexperiments performed in a model of PHN in the isolated
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,15 kD PLA2 activity, which in cell extracts was associ- eicosanoids in glomerulonephritis [36, 37], but studies
on PLA2 in immune glomerular injury are very limited.ated primarily with the particulate fraction, and quantita-
tively represented ,10% of cPLA2 activity [22]. The ,15 In addition to the present study, Hirose et al demon-
strated that cPLA2 mRNA was up-regulated in anti-kD PLA2 activity is in keeping with sPLA2. Conse-
quently, in this study, we focused on three specific sPLA2 Thy-1 glomerulonephritis, however, levels of protein or
isoforms: group IB, which is reported to be found in the enzymatic activity were not measured [38].
kidney [24]; group IIA, which may also be expressed in We have reported that acute or chronic incubation of
the kidney and is involved in inflammatory processes cultured GEC with complement leads to production of
[2–4, 24]; and the recently described group V sPLA2, prostaglandin E2 (PGE2) [22], and that PGE2 generation
which is closely related to the group IIA isoform [3, 4]. is coupled with the activation of cPLA2. Moreover, acti-
The group IIA and V sPLA2s appear to be functionally vation of cPLA2 is the critical rate-limiting step in eicosa-
redundant [33]. In resting GEC, group IB, IIA, or V noid production in GEC [20, 22]. We and others have
sPLA2 mRNAs were not detected consistently. Although also reported that by analogy to GEC in culture, glomer-
PMA 1 cycloheximide was able to “superinduce” group uli from rats with PHN show increased production of
IIA and V sPLA2 mRNAs, PMA or LPS (similarly to eicosanoids, including PGE2 and TxA2 (abstracts; Ta-
complement) had trivial or no effects on sPLA2 mRNA kano and Cybulsky, J Am Soc Nephrol 9:486A, 1998;
expression or AA release, suggesting that physiological Takano et al, J Am Soc Nephrol 10:538A, 1999) [10–12].
induction of sPLA2 genes does not occur in GEC (Fig. The present study thus provides an important insight
3). Moreover, the experiments employing GEC that into the pathway of PGE2 and TxA2 generation in vivo.
overexpress group IIA sPLA2 indicate that sPLA2 activ- In some models of experimental membranous nephropa-
ity was not regulated in a post-translational manner (Fig. thy, inhibition of cyclooxygenase or Tx synthase, or shift-
5). Further studies will be necessary to determine why ing production of dienoic prostanoids to inactive metab-
C5b-9 does not enhance sPLA2 activity in GEC, although olites using a fish oil diet reduce urinary protein excretion
this failure cannot be accounted for by lack of requisite [11–14]. Accordingly, complement-mediated activation
cPLA2 activation. It should be noted that in contrast to of PLA2 and production of glomerular eicosanoids ap-
the sPLA2s, in GEC, C5b-9 is able to induce expression pear to exacerbate glomerular injury. The exact mecha-
of another gene relevant to AA metabolism, namely nisms for these effects are not known, but may involve
cyclooxygenase-2 (abstracts; Takano and Cybulsky, J a TxA2-mediated increase in glomerular transcapillary
Am Soc Nephrol 9:486A, 1998; Takano et al, J Am Soc pressure, which can enhance protein leakage through
Nephrol 10:538A, 1999). the glomerular capillary wall. Studies in cultured GEC
Results analogous to those in cultured GEC were evi- indicate that activation of cPLA2 may directly exacerbate
dent in C5b-9-mediated GEC injury in vivo, which occurs complement-dependent GEC injury [22]. Several path-
in the PHN model of membranous nephropathy. PLA2 ways may be responsible for cytotoxic consequences of
activity was increased in glomeruli of rats with PHN, as cPLA2 activation. For example, release of free fatty acids
compared with control (Fig. 6). Although the increase and lysophospholipids, or enhanced influx of ions (such
was only ,50% above baseline, it should be noted that as Ca21) secondary to membrane perturbation by cPLA2
the total baseline glomerular activity may include PLA2 may be toxic to cells, impairing their bioenergetic capac-
found in mesangial and endothelial cells in addition to ity [1]. In support of this view are studies in cPLA2
GEC, while the increased portion of PLA2 activity in knockout mice showing that the mice deficient in cPLA2
PHN most likely originates only in the GEC. Moreover, had a reduction in postischemic brain injury, as com-
the magnitude of the increase in PLA2 activity in PHN pared with their wild-type counterparts [39]. Possibly,
is in keeping with changes in other in vivo models, such similar consequences of cPLA2 activation may also con-
as renal ischemia-reperfusion or cirrhosis [34, 35]. Addi- tribute to the pathogenesis of glomerular injury in mem-
tional characterization of glomerular PLA2 activity in branous nephropathy. Development of a C5b-9-depen-
PHN, including studies on substrate selectivity, effects dent model of membranous nephropathy in the mouse
of selective inhibitors, and Ca21-dependence, indicated would allow use of cPLA2 knockout mice to further de-
that the PLA2 activity was most consistent with cPLA2 fine the role of this enzyme in complement-mediated
(Fig. 6). Since we did not detect a change in cPLA2 cytotoxicity and immune glomerular injury.
protein expression in PHN (Fig. 7), the results indicate
that the enhanced cPLA2 activity was most likely due to
a stable post-translational modification of the enzyme ACKNOWLEDGMENTS
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